MX392605B - Compuestos, composiciones y metodos para el tratamiento de enfermedades. - Google Patents
Compuestos, composiciones y metodos para el tratamiento de enfermedades.Info
- Publication number
- MX392605B MX392605B MX2019000216A MX2019000216A MX392605B MX 392605 B MX392605 B MX 392605B MX 2019000216 A MX2019000216 A MX 2019000216A MX 2019000216 A MX2019000216 A MX 2019000216A MX 392605 B MX392605 B MX 392605B
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- compounds
- methods
- diseases
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662359039P | 2016-07-06 | 2016-07-06 | |
| US201662363118P | 2016-07-15 | 2016-07-15 | |
| US201662403530P | 2016-10-03 | 2016-10-03 | |
| US201662411424P | 2016-10-21 | 2016-10-21 | |
| US201762444141P | 2017-01-09 | 2017-01-09 | |
| US201762462679P | 2017-02-23 | 2017-02-23 | |
| US201762470746P | 2017-03-13 | 2017-03-13 | |
| US201762508846P | 2017-05-19 | 2017-05-19 | |
| PCT/US2017/040882 WO2018009648A1 (en) | 2016-07-06 | 2017-07-06 | Compounds, compositions, and methods for the treatment of disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019000216A MX2019000216A (es) | 2019-11-12 |
| MX392605B true MX392605B (es) | 2025-03-11 |
Family
ID=60913147
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019000216A MX392605B (es) | 2016-07-06 | 2017-07-06 | Compuestos, composiciones y metodos para el tratamiento de enfermedades. |
| MX2022006260A MX2022006260A (es) | 2016-07-06 | 2019-01-07 | Compuestos, composiciones y metodos para el tratamiento de enfermedades. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022006260A MX2022006260A (es) | 2016-07-06 | 2019-01-07 | Compuestos, composiciones y metodos para el tratamiento de enfermedades. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11033569B2 (OSRAM) |
| EP (1) | EP3481402A4 (OSRAM) |
| JP (3) | JP7100227B2 (OSRAM) |
| KR (1) | KR102569881B1 (OSRAM) |
| CN (1) | CN109843302B (OSRAM) |
| AU (1) | AU2017293781B2 (OSRAM) |
| CA (1) | CA3029644A1 (OSRAM) |
| IL (1) | IL264049B2 (OSRAM) |
| MX (2) | MX392605B (OSRAM) |
| MY (1) | MY199689A (OSRAM) |
| NZ (1) | NZ750055A (OSRAM) |
| SG (1) | SG11201811709WA (OSRAM) |
| TW (1) | TWI689514B (OSRAM) |
| WO (1) | WO2018009648A1 (OSRAM) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ746112A (en) | 2016-03-18 | 2023-01-27 | Immune Sensor Llc | Cyclic di-nucleotide compounds and methods of use |
| AU2017293781B2 (en) * | 2016-07-06 | 2022-12-22 | Invox Pharma Limited | Compounds, compositions, and methods for the treatment of disease |
| JOP20170192A1 (ar) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
| SG11201908813QA (en) | 2017-04-13 | 2019-10-30 | Aduro Biotech Holdings Europe B V | Anti-sirp alpha antibodies |
| AR113224A1 (es) | 2017-04-28 | 2020-02-19 | Novartis Ag | Conjugados de anticuerpo que comprenden un agonista de sting |
| CN111566119A (zh) | 2017-11-10 | 2020-08-21 | 武田药品工业有限公司 | Sting调节剂化合物以及制备和使用方法 |
| US10966999B2 (en) | 2017-12-20 | 2021-04-06 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| CA3106110A1 (en) * | 2018-07-10 | 2020-01-16 | Sperovie Biosciences, Inc. | Compounds, compositions, and methods for the treatment of disease |
| TW202030199A (zh) * | 2018-07-17 | 2020-08-16 | 美商健生生物科技公司 | 作為ｓｔｉｎｇ促效劑之環狀二核苷酸 |
| KR102567590B1 (ko) | 2018-09-06 | 2023-08-17 | 다이이찌 산쿄 가부시키가이샤 | 신규 고리형 디뉴클레오티드 유도체 및 그 항체 약물 콘쥬게이트 |
| KR102755652B1 (ko) | 2018-09-21 | 2025-01-21 | 상하이 드 노보 파마테크 컴퍼니 리미티드 | 고리형 디뉴클레오티드 유사체, 이의 약학 조성물 및 용도 |
| US11110106B2 (en) | 2018-10-29 | 2021-09-07 | Venenum Biodesign, LLC | Sting agonists for treating bladder cancer and solid tumors |
| AU2019371206A1 (en) | 2018-10-29 | 2021-05-27 | Venenum Biodesign, LLC | Novel sting agonists |
| JP2022509929A (ja) | 2018-10-31 | 2022-01-25 | ノバルティス アーゲー | Ｓｔｉｎｇアゴニストを含むｄｃ－ｓｉｇｎ抗体コンジュゲート |
| CN111423483B (zh) * | 2019-01-10 | 2025-01-17 | 英诺生物制药(深圳)有限公司 | 环二核苷酸前药分子及其制备方法和应用 |
| US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| AU2020231115B2 (en) * | 2019-03-07 | 2025-02-20 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| DK3934757T3 (da) | 2019-03-07 | 2023-04-17 | Inst Of Organic Chemistry And Biochemistry Ascr V V I | 2'3'-cykliske dinukleotider og prodrugs deraf |
| JP7621974B2 (ja) | 2019-05-09 | 2025-01-27 | アリゴス セラピューティクス インコーポレイテッド | Ｓｔｉｎｇモジュレータとしての修飾環状ジヌクレオシド化合物 |
| AU2020310853A1 (en) | 2019-07-05 | 2022-01-27 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
| BR112022015283A2 (pt) | 2020-03-06 | 2022-09-20 | Daiichi Sankyo Co Ltd | Conjugado anticorpo-fármaco incluindo derivados de dinucleotídeos cíclicos |
| TW202200136A (zh) | 2020-04-10 | 2022-01-01 | 日商小野藥品工業股份有限公司 | 癌治療方法 |
| CN111909223A (zh) * | 2020-07-17 | 2020-11-10 | 清华大学 | 环二核苷酸共价修饰物及其制备方法和应用 |
| WO2022032191A1 (en) | 2020-08-07 | 2022-02-10 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
| KR20230061360A (ko) | 2020-09-02 | 2023-05-08 | 다이이찌 산쿄 가부시키가이샤 | 신규 엔도-β-N-아세틸글루코사미니다아제 |
| EP4240488A1 (en) | 2020-11-09 | 2023-09-13 | Takeda Pharmaceutical Company Limited | Antibody drug conjugates |
| TW202346322A (zh) | 2022-03-02 | 2023-12-01 | 日商第一三共股份有限公司 | 含Ｆｃ分子之製造方法 |
| EP4582106A1 (en) | 2022-08-29 | 2025-07-09 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate including mutant fc region |
| WO2024076728A1 (en) * | 2022-10-06 | 2024-04-11 | Dana-Farber Cancer Institute, Inc. | Cyclic nucleotides and uses thereof |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2257704B (en) * | 1991-07-18 | 1995-03-01 | Erba Carlo Spa | Cyclic oligonucleotides phosphorothioates |
| EP2371834B1 (en) * | 2003-06-11 | 2016-02-17 | Idera Pharmaceuticals, Inc. | Stabilized immunomodulatory oligonucleotides |
| US7592326B2 (en) * | 2004-03-15 | 2009-09-22 | Karaolis David K R | Method for stimulating the immune, inflammatory or neuroprotective response |
| CA2560058C (en) * | 2004-03-15 | 2011-10-18 | David K.R. Karaolis | A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis |
| WO2011003025A1 (en) * | 2009-07-01 | 2011-01-06 | Rutgers, The State University Of New Jersey | Synthesis of cyclic diguanosine monophosphate and thiophosphate analogs thereof |
| CN102199183B (zh) * | 2010-03-26 | 2013-12-18 | 北京大学 | 环二鸟苷酸及其类似物和制备方法 |
| AU2013271375B2 (en) | 2012-06-08 | 2018-03-22 | Aduro Biotech, Inc. | Compositions and methods for cancer immunotherapy |
| AU2013358892B2 (en) | 2012-12-13 | 2018-06-21 | Aduro Biotech, Inc. | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
| KR102255996B1 (ko) * | 2012-12-19 | 2021-05-26 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 포유동물 시클릭 디-뉴클레오티드 신호 경로의 약학적 표적화 |
| US10876161B2 (en) * | 2012-12-20 | 2020-12-29 | Hills Pet Nutrition, Inc. | Pattern recognition receptor expression as a measure of systemic health |
| JP6153116B2 (ja) * | 2013-01-09 | 2017-06-28 | 国立大学法人東北大学 | トリアゾール連結型環状ジヌクレオチド類縁体 |
| KR20140100417A (ko) * | 2013-02-05 | 2014-08-14 | 닛토덴코 가부시키가이샤 | 경피 투여용 백신 조성물 |
| ES2822584T3 (es) * | 2013-05-03 | 2021-05-04 | Univ California | Inducción de dinucleótidos cíclicos del interferón tipo I |
| PE20160080A1 (es) | 2013-05-18 | 2016-02-21 | Aduro Biotech Inc | Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon |
| CN103864910B (zh) * | 2014-03-03 | 2016-01-20 | 中国科学院南海海洋研究所 | 一种新型特异结合lps的贝类模式识别受体lrrp |
| ES3040431T3 (en) | 2014-03-12 | 2025-10-31 | Yeda Res & Dev | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
| JP6462006B2 (ja) | 2014-06-04 | 2019-01-30 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｓｔｉｎｇのモジュレーターとしての環式ジヌクレオチド |
| WO2016096577A1 (en) | 2014-12-16 | 2016-06-23 | Invivogen | Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment |
| CN107148424B (zh) * | 2014-12-16 | 2021-01-08 | 凯拉治疗股份公司 | 用于诱导细胞因子的环状二核苷酸 |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| US10449211B2 (en) * | 2015-03-10 | 2019-10-22 | Aduro Biotech, Inc. | Compositions and methods for activating “stimulator of interferon gene”—dependent signalling |
| EA034786B1 (ru) | 2015-08-13 | 2020-03-20 | Мерк Шарп И Доум Корп. | Циклические динуклеотидные соединения в качестве агонистов sting |
| EP3368072A4 (en) | 2015-10-28 | 2019-07-03 | Aduro BioTech, Inc. | COMPOSITIONS AND METHOD FOR ACTIVATING SIGNALING DEPENDENT ON THE STIMULATOR OF THE INTERFERON GENE |
| RU2020113165A (ru) * | 2015-12-03 | 2020-06-09 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Циклические пуриновые динуклеотиды в качестве модуляторов sting |
| CN106540260A (zh) | 2015-12-09 | 2017-03-29 | 聊城市奥润生物医药科技有限公司 | 干扰素基因刺激蛋白（sting）激动剂在抗阿尔兹海默症中的应用 |
| US20180369268A1 (en) * | 2015-12-16 | 2018-12-27 | Aduro Biotech, Inc. | Methods for identifying inhibitors of "stimulator of interferon gene"- dependent interferon production |
| US10723756B2 (en) | 2016-01-11 | 2020-07-28 | Innate Tumor Immunity Inc. | Cyclic dinucleotides for treating conditions associated with STING activity such as cancer |
| SMT202500412T1 (it) | 2016-01-11 | 2025-11-10 | Innate Tumor Immunity Inc | Dinucleotidi ciclici per il trattamento di condizioni associate all’attività di sting quali il cancro |
| AU2017225769B2 (en) | 2016-03-02 | 2023-01-05 | The Board Of Regents Of The University Of Texas System | Sting activating nanovaccine for immunotherapy |
| US11098077B2 (en) | 2016-07-05 | 2021-08-24 | Chinook Therapeutics, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| AU2017293781B2 (en) * | 2016-07-06 | 2022-12-22 | Invox Pharma Limited | Compounds, compositions, and methods for the treatment of disease |
| WO2018045204A1 (en) | 2016-08-31 | 2018-03-08 | Ifm Therapeutics, Inc | Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity |
| TN2020000158A1 (en) | 2016-10-04 | 2022-04-04 | Merck Sharp & Dohme | BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS |
| JOP20170192A1 (ar) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
| CA3047394A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Combinations of pd-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment |
| CA3047113A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Cyclic dinucleotide sting agonists for cancer treatment |
| EP3585379A4 (en) | 2017-02-21 | 2020-12-02 | Board of Regents, The University of Texas System | CYCLIC DINUCLEOTIDES USED AS AGONISTS OF THE INTERFERON-DEPENDENT SIGNALING STIMULATOR |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| EP3621624B1 (en) | 2017-05-12 | 2023-08-30 | Merck Sharp & Dohme LLC | Cyclic di-nucleotide compounds as sting agonists |
| US20200138827A1 (en) | 2017-06-22 | 2020-05-07 | Curadev Pharma Limited | Small molecule modulators of human sting |
| AU2018288018C1 (en) | 2017-06-22 | 2022-10-20 | Curadev Pharma Limited | Small molecule modulators of human STING |
| US20200172483A1 (en) | 2017-06-22 | 2020-06-04 | Curadev Pharma Limited | Heterocyclic small molecule modulators of human sting |
| US11707531B2 (en) * | 2017-09-11 | 2023-07-25 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
-
2017
- 2017-07-06 AU AU2017293781A patent/AU2017293781B2/en active Active
- 2017-07-06 IL IL264049A patent/IL264049B2/en unknown
- 2017-07-06 MY MYPI2019000212A patent/MY199689A/en unknown
- 2017-07-06 CA CA3029644A patent/CA3029644A1/en active Pending
- 2017-07-06 JP JP2019520928A patent/JP7100227B2/ja active Active
- 2017-07-06 US US16/315,472 patent/US11033569B2/en active Active
- 2017-07-06 WO PCT/US2017/040882 patent/WO2018009648A1/en not_active Ceased
- 2017-07-06 KR KR1020197003440A patent/KR102569881B1/ko active Active
- 2017-07-06 MX MX2019000216A patent/MX392605B/es unknown
- 2017-07-06 EP EP17824876.1A patent/EP3481402A4/en active Pending
- 2017-07-06 TW TW106122757A patent/TWI689514B/zh active
- 2017-07-06 SG SG11201811709WA patent/SG11201811709WA/en unknown
- 2017-07-06 CN CN201780054031.7A patent/CN109843302B/zh active Active
- 2017-07-06 NZ NZ750055A patent/NZ750055A/en unknown
-
2019
- 2019-01-07 MX MX2022006260A patent/MX2022006260A/es unknown
-
2021
- 2021-06-04 US US17/339,484 patent/US11744845B2/en active Active
-
2022
- 2022-05-12 JP JP2022078657A patent/JP2022106989A/ja active Pending
-
2023
- 2023-09-26 JP JP2023162456A patent/JP7749629B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TWI689514B (zh) | 2020-04-01 |
| EP3481402A1 (en) | 2019-05-15 |
| KR20190032408A (ko) | 2019-03-27 |
| CN109843302A (zh) | 2019-06-04 |
| JP2023182645A (ja) | 2023-12-26 |
| NZ750055A (en) | 2025-08-29 |
| JP7100227B2 (ja) | 2022-07-13 |
| CA3029644A1 (en) | 2018-01-11 |
| TW201805295A (zh) | 2018-02-16 |
| IL264049B1 (en) | 2023-07-01 |
| MX2019000216A (es) | 2019-11-12 |
| IL264049B2 (en) | 2023-11-01 |
| US11744845B2 (en) | 2023-09-05 |
| MY199689A (en) | 2023-11-17 |
| AU2017293781B2 (en) | 2022-12-22 |
| IL264049A (en) | 2019-01-31 |
| JP2022106989A (ja) | 2022-07-20 |
| CN109843302B (zh) | 2022-11-29 |
| US20190262372A1 (en) | 2019-08-29 |
| MX2022006260A (es) | 2022-06-29 |
| AU2017293781A1 (en) | 2019-02-07 |
| JP2019532084A (ja) | 2019-11-07 |
| US11033569B2 (en) | 2021-06-15 |
| US20220054523A1 (en) | 2022-02-24 |
| KR102569881B1 (ko) | 2023-08-22 |
| SG11201811709WA (en) | 2019-01-30 |
| JP7749629B2 (ja) | 2025-10-06 |
| WO2018009648A1 (en) | 2018-01-11 |
| EP3481402A4 (en) | 2020-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX392605B (es) | Compuestos, composiciones y metodos para el tratamiento de enfermedades. | |
| CR20190071A (es) | Compuestos, composiciones y métodos para el tratamiento de enfermedades | |
| ECSP21073266A (es) | Compuestos, composiciones y métodos para el tratamiento de enfermedad | |
| CO2022002759A2 (es) | Antagonistas de hpk1 y sus usos | |
| CL2018002359A1 (es) | Métodos para usar agonistas de fxr | |
| CL2018001845A1 (es) | Moduladores de la 5'-nucleotidasa, ecto y su uso | |
| CL2019002368A1 (es) | Composiciones y métodos para el tratamiento de cáncer. | |
| CL2018001252A1 (es) | Métodos para tratar esclerosis múltiple usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton | |
| MX2024011869A (es) | Anticuerpos anti-tau y metodos de uso | |
| MX2019001672A (es) | Composiciones de poxvirus quiméricos y usos de las mismas. | |
| MX2019007243A (es) | Inhibidores de ectonucleotidasa y metodos de uso de los mismos. | |
| CO2018005954A2 (es) | Compuestos heteroaromáticos como inhibidores de btk | |
| UY36458A (es) | Anticuerpos humanos para hemaglutinina influenza. | |
| MX373341B (es) | INHIBIDORES DE PROTEíNA CINASA 2 ACTIVADA POR PROTEíNA CINASA ACTIVADA POR MITóGENO (MK2) Y SUS USOS. | |
| CO2019009787A2 (es) | Anticuerpos contra triptasa, composiciones de estos y usos de estos | |
| MX2016010433A (es) | Anticuerpos anti-jagged1 y metodos de uso. | |
| CL2019001381A1 (es) | Método para el tratamiento de glomeruloesclerosis segmentaria focal. | |
| MX2017013874A (es) | Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa. | |
| DOP2017000120A (es) | 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139 | |
| CO2019013823A2 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
| CL2021001198A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
| CL2018002023A1 (es) | Uso de moduladores de receptores de gabaa para el tratamiento de picor. | |
| CL2023000892A1 (es) | Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b (divisional). | |
| CL2019000049A1 (es) | Procesos para la preparación de oxipicolinamidas 4 - alkoxi - (acil o aquil). | |
| CO2019008110A2 (es) | Activador de nrf2 |